CPRX

Catalyst Pharmaceuticals (NASDAQ: CPRX) showed a loss in earnings since Q1, totaling $10.28 million. Sales, on the other hand, increased by 1.61% to $29.61 million during Q2. In Q1, Catalyst Pharmaceuticals earned $10.70 million and total sales reached $29.14 million.What Is ROCE? Changes in earnings and sales indicate shifts in Catalyst Pharmaceuticals's Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q2, Catalyst Pharmaceuticals posted an ROCE of 0.09%.It is important to keep in mind ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but several factors could affect earnings and sales in the near future.View more earnings on CPRXROCE is an important metric for the comparison of similar companies. A relatively high ROCE shows Catalyst Pharmaceuticals is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and earnings per share growth.In Catalyst Pharmaceuticals's case, the positive ROCE ratio will be something investors pay attention to before making long-term financial decisions.Q2 Earnings Recap Catalyst Pharmaceuticals reported Q2 earnings per share at $0.09/share, which beat analyst predictions of $0.08/share.See more from Benzinga * Click here for options trades from Benzinga * Looking Into American Airlines Group's Return On Capital Employed * ROCE Insights For Bed Bath & Beyond(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Catalyst Pharmaceuticals (CPRX) has filed patent infringement litigation in two U.S. district courts against Jacobus Pharmaceuticals and PantherRx Rare LLC, respectively, related to their marketing of Ruzurgi (amifampridine, 10 mg),

CORAL GABLES, Fla., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that it has filed a lawsuit in the U.S. District Court for New Jersey against Jacobus Pharmaceuticals, Inc. (Jacobus), and a lawsuit in the U.S. District Court for the Western District of Pennsylvania against PantherRx Rare LLC (PantherRx) for infringement of U.S. Patent No. 10,793,893 (the ’893 patent). The ’893 patent is exclusively licensed to Catalyst Pharmaceuticals and covers certain methods for treating disease using amifampridine drug products, including Catalyst’s Firdapse® product, in patients who are slow metabolizers of amifampridine. The lawsuit arises from Jacobus’ and PantherRx’s sales and marketing of Ruzurgi® (amifampridine, 10 mg). The lawsuit alleges that the Ruzurgi® product infringes the ‘893 patent when administered in accordance with its product labeling. The lawsuit seeks damages and injunctive relief to prevent further marketing of Ruzurgi® in violation of Catalyst’s patent rights."Catalyst has invested significant resources in neuromuscular drug discovery and in building an intellectual property portfolio that aids in the discovery and development of drugs for the treatment of rare neurodegenerative diseases that are without a safe and effective FDA approved therapy," said Patrick J. McEnany, Chairman and CEO of Catalyst. "We intend to diligently and vigorously protect our patent rights for the benefit of our company and our stockholders and prevent infringing use by others. Catalyst remains confident in its patent portfolio, and has filed several additional patent applications claiming priority from the ‘893 patent to enhance the protection of the Firdapse® patent estate.”About Firdapse® Firdapse® (amifampridine) 10 mg tablets is an oral, nonspecific, voltage-dependent, potassium (K+) channel blocker that causes depolarization of the presynaptic membrane and slows or inhibits repolarization. This action results in the opening of slow voltage-dependent calcium (Ca2+) channels, allowing for a subsequent influx of Ca2+. In turn, it induces the exocytosis of synaptic vesicles containing Acetylcholine (ACh) to release more ACh into the synaptic cleft, enhancing neuromuscular transmission, and providing for improved muscle function.About Catalyst PharmaceuticalsCatalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), anti-MuSK antibody positive myasthenia gravis (MuSK-MG), and spinal muscular atrophy (SMA) Type 3. Catalyst's new drug application for Firdapse® (amifampridine) 10 mg tablets for the treatment of adults with LEMS was approved in November 2018 by the U.S. Food & Drug Administration ("FDA"), and Firdapse® is commercially available in the United States. Further, Canada’s national healthcare regulatory agency, Health Canada, recently approved the use of Firdapse® (amifampridine) for the treatment of patients in Canada with LEMS.Firdapse® is currently being evaluated in clinical trials for the treatment of MuSK-MG and SMA Type 3 and has received Orphan Drug Designation from the FDA for myasthenia gravis.Forward-Looking StatementsThis press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including (i) the scope of protection from competition provided by the patent, (ii) whether Catalyst’s lawsuits will be successful, and (iii) those factors described in Catalyst's Annual Report on Form 10-K for fiscal year 2019 and its other filings with the U.S. Securities and Exchange Commission (SEC), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.  CONTACT: Investor Contact Brian Korb Solebury Trout (646) 378-2923 bkorb@troutgroup.com Company Contact Patrick J. McEnany Catalyst Pharmaceuticals Chief Executive Officer (305) 420-3200 pmcenany@catalystpharma.com Media Contact David Schull Russo Partners (212) 845-4271 david.schull@russopartnersllc.com

Catalyst Pharmaceuticals has dipped in recent months due to the lack of positive catalysts for the stock.This has brought renewed value to CPRX with Wall Street analysts predicting as much as 145% upside over the long term.Catalyst Pharma has reduced downside risks in comparison to other small-cap biotech plays as they already have an approved product on the market in Firdapse.

With its stock down 34% over the past three months, it is easy to disregard Catalyst Pharmaceuticals (NASDAQ:CPRX...

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 823 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]

United States Patent and Trademark Office issued a new U.S. patent to Catalyst Pharmaceuticals (CPRX) for Firdapse (amifampridine), Patent No. 10,793,893, Methods of Administering 3,4-Diaminopyridine; expires on April 7, 2034.“This patent is directed to